ArticleFrontiers in pharmacology2025
Cerebrolysin, hemorrhagic transformation, and anticoagulation timing after reperfusion therapy in stroke:
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The optimal timing of anticoagulation resumption after acute ischemic stroke remains uncertain, particularly in patients at elevated risk of hemorrhagic transformation (HT). Although Cerebrolysin reduces HT incidence, its influence on dynamic HT risk and the safe anticoagulation window remains unclear. Methods: This Results: In high-risk patients, Cerebrolysin significantly reduced symptomatic HT (HR 0.245; 95% CI 0.072-0.837; Conclusion: In IVT-treated MCA stroke patients with HTI 1-4, Cerebrolysin may reduce HT hazard and advance the risk-equilibrium point by approximately 1-2 days. These findings are preliminary and hypothesis-generating, suggesting that Cerebrolysin may allow earlier-but individualized-anticoagulation resumption in selected high-risk patients, pending prospective validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.